Synergy CHC Corp.
SNYRQ- Exchange
- OTC
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001562733
No open-market purchases or sales by Synergy CHC Corp. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesSNYR
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Synergy CHC Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Synergy CHC Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baumeler Alfred | President | – | Jul 1, 2026 | 1 |
| Fickett Jaime | Chief Financial Officer | – | Jul 1, 2026 | 1 |
| Ross Jack | CEO and Chairman | 410,507 | Jul 1, 2026 | 1 |
| Kaushal Nitin | Director | 306,433 | Apr 24, 2026 | 1 |
| Thompson Teresa Brigid | Director | 25,824 | Apr 23, 2026 | 1 |
| Knight Therapeutics Inc | 10% Owner | – | Jun 13, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2025 (view filing) | Jun 11-Jul 30 | 50 daysLate | Ross JackCEO and Chairman | PPurchaseCommon Stock, par value $0.00001 per share | +27.9K | $2.85 | +$79.6K | +7.3%410.5K after | 24 lots |
| Jun 13, 2025 (view filing) | Jun 11 | 2 days | Knight Therapeutics Inc10% Owner | PPurchase | +428.6K | $0.00 | $0 | –428.6K after | Derivative |
| Jun 11, 2025 (view filing) | Jun 2-10 | 9 daysLate | Ross JackCEO and Chairman | PPurchaseCommon Stock, par value $0.00001 per share | +16.1K | $1.85 | +$29.8K | +4.4%382.6K after | 6 lots |
| May 21, 2025 (view filing) | Apr 11-May 15 | 40 daysLate | Ross JackCEO and Chairman | PPurchaseCommon Stock, par value $0.00001 per share | +5.30K | $2.05 | +$10.9K | +1.5%366.5K after | 12 lots |
| May 21, 2025 (view filing) | Feb 21-Apr 10 | 89 daysLate | Ross JackCEO and Chairman | PPurchaseCommon Stock, par value $0.00001 per share | +14.3K | $2.74 | +$39.3K | +4.1%361.2K after | 30 lots |
| Mar 3, 2025 (view filing) | Jan 23-Feb 21 | 39 daysLate | Ross JackCEO and Chairman | PPurchaseCommon Stock, par value $0.00001 per share | +15.2K | $3.92 | +$59.5K | +4.6%346.9K after | 20 lots |
| Mar 3, 2025 (view filing) | Nov 25, 2024-Jan 22, 2025 | 98 daysLate | Ross JackCEO and Chairman | PPurchaseCommon Stock, par value $0.00001 per share | +5.17K | $4.92 | +$25.5K | +1.6%331.7K after | 30 lots |
| Oct 24, 2024 (view filing) | Oct 24 | Same day | Ross JackCEO and Chairman | PPurchaseCommon Stock, par value $0.00001 per share | +300.0K | $9.00 | +$2.70M | New position300.0K after |